Exact Sciences price target lowered to $65 from $75 at Barclays

Barclays lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $75 and keeps an Overweight rating on the shares as part of a Q2 preview for the life science and diagnostic tools sector. Sentiment on the group is shifting more positive on the notion that many of the unknown headwinds around policy changes, namely National Institutes of Health budgetary cuts and pharma tariffs, are likely to prove less severe than feared, the analyst tells investors in a research note. Barclays still favors businesses exposed to commercial and clinical volumes, mainly bioprocessing and diagnostics.